Solasia Pharma K.K., a specialty pharmaceutical company, develops, imports/exports, and markets pharmaceutical products and medical devices, etc. in Japan. It offers SP-01 Sancuso, a transdermal delivery system that delivers the anti-emetic and granisetron into the patients bloodstream to patients receiving chemotherapy; and SP-02 Darinaparsin, a mitochondrial-targeted agent for the treatment of various hematologic and solid cancers, as well as SP-03 episil, an oral liquid for the treatment of pain associated with oral mucositis. The company was founded in 2006 and is based in Tokyo, Japan.
Stock data | 2024 | Change |
---|---|---|
Price | $0.25030635674191176 | N/A |
Market Cap | $16.17M | N/A |
Shares Outstanding | 64.61M | N/A |
Employees | 16.00 | N/A |